The role of resistin in colorectal cancer

Clinica Chimica Acta

Volumn 413, Issue 7-8, 2012, Pages 760-764

  Danese, Elisa ^a   Montagnana, Martina ^a   Minicozzi, Anna Maria ^a   Bonafini, Sara ^a   Ruzzenente, Orazio ^a   Gelati, Matteo ^a   De Manzoni, Giovanni ^a   Lippi, Giuseppe ^b   Guidi, Gian Cesare ^a  

^a UNIVERSITY OF VERONA   (Italy)

^b UNIVERSITY HOSPITAL OF PARMA   (Italy)

Author keywords

Adipocytokine; Colorectal cancer; Inflammation; Metabolic syndrome; Resistin

Indexed keywords

ADIPOCYTOKINE; C REACTIVE PROTEIN; GLUCOSE; LIPID; RESISTIN;

ADULT; ARTICLE; BLOOD PRESSURE MEASUREMENT; BODY HEIGHT; BODY WEIGHT; CANCER PREVENTION; CANCER RISK; CANCER STAGING; CLINICAL ARTICLE; COLORECTAL CANCER; CONTROLLED STUDY; DISEASE ASSOCIATION; FEMALE; GLUCOSE BLOOD LEVEL; HUMAN; LIPID BLOOD LEVEL; MALE; ONCOLOGICAL PARAMETERS; PREDICTOR VARIABLE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN FUNCTION; TUMOR GROWTH; WAIST CIRCUMFERENCE;

ADULT; AGED; BLOOD GLUCOSE; C-REACTIVE PROTEIN; CASE-CONTROL STUDIES; COLORECTAL NEOPLASMS; FEMALE; HUMANS; LIPIDS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; RESISTIN;

EID: 84857641824     PISSN: 00098981     EISSN: 18733492     Source Type: Journal    
DOI: 10.1016/j.cca.2012.01.019     Document Type: Article

References (52)

1. Jemal A., Bray F., Center M.M., Ferlay J., Ward E. Forman D CA. Global cancer statistics. Cancer J Clin 2011, 61:69-90.
2. Bianchini F., Kaaks R., Vainio H. Overweight, obesity, and cancer risk. Lancet Oncol 2002, 3:565-574.
3. Calle E.E., Kaaks R. Overweight, obesity and cancer: epidemiological evidence and proposed mechanisms. Nat Rev Cancer 2004, 4:579-591.
4. Gunter M.J., Leitzmann M.F. Obesity and colorectal cancer: epidemiology, mechanisms and candidate genes. J Nutr Biochem 2006, 17:145-156.
5. Trayhurn P., Beattie J.H. Physiological role of adipose tissue: white adipose tissue as an endocrine and secretory organ. Proc Nutr Soc 2001, 60:329-339.
6. Wozniak S., Gee L., Wachtel M., Frezza E. Adipose tissue: the new endocrine organ? A review article. Dig Dis Sci 2009, 54:1847-1856.
7. Trayhurn P., Wood I.S. Adipokines: inflammation and the pleiotropic role of white adipose tissue. Br J Nutr 2004, 92:347-355.
8. Trayhurn P., Wood I.S. Signalling role of adipose tissue: adipokines and inflammation in obesity. Biochem Soc Trans 2005, 33:1078-1081.
9. Hauner H. Secretory factors from human adipose tissue and their functional role. Proc Nutr Soc 2005, 64:163-169.
10. Mutoh M, Teraoka N, Takasu S, et al. Loss of adiponectin promotes intestinal carcinogenesis in Min and wild-type mice. Gastroenterology 2011;140:2000-8).
11. Urbanek M., Du Y., Silander K., et al. Variation in resistin gene promoter not associated with polycystic ovary syndrome. Diabetes 2003, 52:214-217.
12. Steppan C.M., Bailey S.T., Bhat S., et al. The hormone resistin links obesity to diabetes. Nature 2001, 409:307-312.
13. Banerjee R.R., Lazar M.A. Dimerization of resistin and resistin-like molecules is determined by a single cysteine. J Biol Chem 2001, 276:25970-25973.
14. Patel S.D., Rajala M.W., Rossetti L., Scherer P.E., Shapiro L. Disulfide-dependent multimeric assembly of resistin family hormones. Science 2004, 304:1154-1158.
15. Vozarova de Courten B, Degawa-Yamauchi M, Considine RV, Tataranni PA. High serum resistin is associated with an increase in adiposity but not a worsening of insulin resistance in Pima Indians. Diabetes 2004;53:1279-84.
16. Degawa-Yamauchi M., Bovenkerk J.E., Juliar B.E., et al. Serum resistin (FIZZ3) protein is increased in obese humans. J Clin Endocrinol Metab 2003, 88:5452-5455.
17. McTernan P.G., Fisher F.M., Valsamakis G., et al. Resistin and type 2 diabetes: regulation of resistin expression by insulin and rosiglitazone and the effects of recombinant resistin on lipid and glucose metabolism in human differentiated adipocytes. J Clin Endocrinol Metab 2003, 88:6098-6106.
18. Fehmann H.C., Heyn J. Plasma resistin levels in patients with type 1 and type 2 diabetes mellitus and in healthy controls. Horm Metab Res 2002, 34:671-673.
19. Lee J.H., Chan J.L., Yiannakouris N., et al. Circulating resistin levels are not associated with obesity or insulin resistance in humans and are not regulated by fasting or leptin administration: cross-sectional and interventional studies in normal, insulin-resistant, and diabetic subjects. J Clin Endocrinol Metab 2003, 88:4848-4856.
20. Chen C.C., Li T.C., Li C.I., Liu C.S., Wang H.J., Lin C.C. Serum resistin level among healthy subjects: relationship to anthropometric and metabolic parameters. Metabolism 2005, 54:471-475.
21. Pagano C., Marin O., Calcagno A., et al. Increased serum resistin in adults with prader-willi syndrome is related to obesity and not to insulin resistance. J Clin Endocrinol Metab 2005, 90:4335-4340.
22. Matsuda M., Kawasaki F., Yamada K., et al. Impact of adiposity and plasma adipocytokines on diabetic angiopathies in Japanese type 2 diabetic subjects. Diabet Med 2004, 21:881-888.
23. Wu H., Yu Z., Qi Q., Li H., Sun Q., Lin X. Joint analysis of multiple biomarkers for identifying type 2 diabetes in middle-aged and older Chinese: a cross-sectional study. BMJ Open. 2011, 1:e000191.
24. Farvid M.S., Ng T.W., Chan D.C., Barrett P.H., Watts G.F. Association of adiponectin and resistin with adipose tissue compartments, insulin resistance and dyslipidaemia. Diabetes Obes Metab 2005, 7:406-413.
25. Bauer S., Neumeier M., Wanninger J., et al. Systemic resistin is increased in type 2 diabetic patients treated with loop diuretics. J Diabetes Complications. 2011, 25:377-381.
26. Malo E., Ukkola O., Jokela M., et al. Resistin is an indicator of the metabolic syndrome according to five different definitions in the Finnish Health 2000 survey. Metab Syndr Relat Disord 2011, 9:203-210.
27. Utzschneider K.M., Carr D.B., Tong J., et al. Resistin is not associated with insulin sensitivity or the metabolic syndrome in humans. Diabetologia 2005, 48:2330-2333.
28. Silha J.V., Krsek M., Skrha J.V., Sucharda P., Nyomba B.L., Murphy L.J. Plasma resistin, adiponectin and leptin levels in lean and obese subjects: correlations with insulin resistance. Eur J Endocrinol 2003, 149:331-335.
29. Heilbronn L.K., Rood J., Janderova L., et al. Relationship between serum resistin concentrations and insulin resistance in nonobese, obese, and obese diabetic subjects. J Clin Endocrinol Metab 2004, 89:1844-1848.
30. Reilly M.P., Lehrke M., Wolfe M.L., Rohatgi A., Lazar M.A., Rader D.J. Resistin is an inflammatory marker of atherosclerosis in humans. Circulation 2005, 111:932-939.
31. Lehrke M., Reilly M.P., Millington S.C., Iqbal N., Rader D.J., Lazar M.A. An inflammatory cascade leading to hyperresistinemia in humans. PloS Med 2004, 1:e45.
32. Sǎlǎgeanu A., Tucureanu C., Lerescu L., et al. Serum levels of adipokines resistin and leptin in patients with colon cancer. J Med Life 2010, 3:416-420.
33. Gonullu G., Kahraman H., Bedir A., Bektas A., Yücel I. Association between adiponectin, resistin, insulin resistance, and colorectal tumors. Int J Colorectal Dis. Int J Colorectal Dis 2010, 25:205-212.
34. Nakajima T.E., Yamada Y., Hamano T., et al. Adipocytokines as new promising markers of colorectal tumors: adiponectin for colorectal adenoma, and resistin and visfatin for colorectal cancer. Cancer Sci 2010, 101:1286-1291.
35. Kumor A., Daniel P., Pietruczuk M., Małecka-Panas E. Serum leptin, adiponectin, and resistin concentration in colorectal adenoma and carcinoma (CC) patients. Int J Colorectal Dis 2009, 24:275-281.
36. Greene F.L., Page D.L., Fleming I.D., Fritz A., Balch C.M., Haller D.G. AJCC cancer staging manual 2002, Springer-Verlag, New York.
37. Alberti K.G., Eckel R.H., Grundy S.M., et al. International Diabetes Federation Task Force on Epidemiology and Prevention, Hational Heart, Lung, and Blood Institute, American Heart Association, World Heart Federation, International Atherosclerosis Society and International Association for the Study of Obesity. Harmonizing the metabolic syndrome: a joint interim statement of the International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; and International Association for the Study of Obesity. Circulation 2009, 120:1640-1645.
38. Wolk A., Gridley G., Svensson M., et al. A prospective study of obesity and cancer risk (Sweden). Cancer Causes Control 2001, 12:13-21.
39. Shen Z., Wang S., Ye Y., et al. Clinical study on the correlation between metabolic syndrome and colorectal carcinoma. ANZ J Surg 2010, 80:331-336.
40. Liu C.S., Hsu H.S., Li C.I., et al. Central obesity and atherogenic dyslipidemia in metabolic syndrome are associated with increased risk for colorectal adenoma in a Chinese population. BMC Gastroenterol 2010, 10:51.
41. Drew JE. Molecular mechanisms linking adipokines to obesity-related colon cancer: focus on leptin. Proc Nutr Soc 2001;1-6.
42. Al Khaldi R.M., Al Mulla F., Al Awadhi S., Kapila K., Mojiminiyi O.A. Associations of single nucleotide polymorphisms in the adiponectin gene with adiponectin levels and cardio-metabolic risk factors in patients with cancer. Dis Markers 2011, 30:197-212.
43. Fenton J.I., Birmingham J.M. Adipokine regulation of colon cancer: adiponectin attenuates interleukin-6-induced colon carcinoma cell proliferation via STAT-3. Mol Carcinog 2010, 49:700-709.
44. Birmingham J.M., Busik J.V., Hansen-Smith F.M., Fenton J.I. Novel mechanism for obesity-induced colon cancer progression. Carcinogenesis 2009, 30:690-697.
45. Savage D.B., Sewter C.P., Klenk E.S., et al. Resistin/ Fizz3 expression in relation to obesity and peroxisome proliferator-activated receptor-gamma action in humans. Diabetes 2001, 50:2199-2202.
46. Jové M., Planavila A., Cabrero A., et al. Reductions in plasma cholesterol levels after fenofibrate treatment are negatively correlated with resistin expression in human adipose tissue. Metabolism 2003, 52:351-355.
47. Vendrell J., Broch M., Vilarrasa N., et al. Resistin, adiponectin, ghrelin, leptin and proinflammatory cytochines: relationships in obesity. Obes Res 2004, 12:962-971.
48. Shetty G.K., Economides P.A., Horton E.S., Mantzoros C.S., Veves A. Circulating adiponectin and resistin levels in relation to metabolic factors, inflammatory markers, and vascular reactivity in diabetic patients and subjects at risk for diabetes. Diabet Care 2004, 27:2450-2457.
49. Kaser S., Kaser A., Sandhofer C.F., Ebenbichler C.F., Tilg H., Patsch J.R. Resistin messanger-RNA is increased by proinflammatory cytokines in vitro. Biochem Biophys Res Commun 2003, 309:286-290.
50. Qi Q., Wang J., Li H. et al..Associations of resistin with inflammatory and fibrinolytic markers, insulin resistance, and metabolic syndrome in middle-aged and older Chinese. Eur J Endocrinol 2008, 159:585-593.
51. Lee S., Choe J.W., Kim H.K., Sung J. High-sensitivity C-reactive protein and cancer. J Epidemiol 2011, 21:161-168.
52. Ledue T.B., Rifai N. Preanalytic and analytic sources of variations in C-reactive protein measurement: implications for cardiovascular disease risk assessment. Clin Chem 2003, 49:1258-1271.